Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
In this study, investigators will be examining the intraocular pressure lowering effect of
brimonidine 0.15% when administered 20min prior to intravitreal anti-VEGF injection.